Angelo Delmonte

9.7k citations

145 papers · 2.7k indexed · h-index 27

Impact in

Oncology top 2%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
Pulmonary and Respiratory Medicine top 1%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment

Papers in

Oncology 91
- Cancer Immunotherapy and Biomarkers 34
- Lung Cancer Research Studies 31
- Colorectal Cancer Treatments and Studies 19
Pulmonary and Respiratory Medicine 104
- Lung Cancer Treatments and Mutations 86
- Lung Cancer Diagnosis and Treatment 16

Co-authors: Lucio Crinò Cristiana Sessa Paola Ulivi Giuseppe Bronte Matteo Canale Gianluca Spitaleri Filippo de Braud Daniele Calistri
Journals: Annals of Oncology (30 papers)Journal of Clinical Oncology (17 papers)Journal of Thoracic Oncology (16 papers)Lung Cancer (6 papers)Cancers (5 papers)
Partner nations: Italy United States United Kingdom

In The Last Decade

Angelo Delmonte

140 papers receiving 2.7k citations

Peers

Countries citing papers authored by Angelo Delmonte

Since Specialization

Citations

This map shows the geographic impact of Angelo Delmonte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angelo Delmonte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angelo Delmonte more than expected).

Fields of papers citing papers by Angelo Delmonte

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Angelo Delmonte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angelo Delmonte. The network helps show where Angelo Delmonte may publish in the future.

Co-authors

The 25 scholars most cited alongside Angelo Delmonte, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Angelo Delmonte Line = papers co-authored together Angelo Delmonte links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation? Nature Reviews Clinical Oncology ·Nicola Normanno, Alessandro Morabito, Anna Maria Rachiglio, Vincenzo Sforza, Lorenza Landi, Emilio Bria, Angelo Delmonte, Federico Cappuzzo, Antonella De Luca	2025	7
2	Clinical implications of the family history in patients with lung cancer: a systematic review of the literature and a new cross-sectional/prospective study design (FAHIC: lung) Journal of Translational Medicine ·Fabrizio Citarella, Kazuki Takada, Priscilla Cascetta, Pierfilippo Crucitti, Roberta Petti, Bruno Vincenzi, Giuseppe Tonini, F.M. Venanzi, Alessandra Bulotta, Sara Oresti, Carlo Greco, Sara Ramella, Lucio Crinò, Angelo Delmonte, Roberto Ferrara, Massimo Di Maïo, Fiorella Gurrieri, Alessio Cortellini	2024	3
3	Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream Frontiers in Immunology ·Luana Calabrò, Giuseppe Bronte, Federica Grosso, Luigi Cerbone, Angelo Delmonte, Fabio Nicolini, Massimiliano Mazza, Anna Maria Di Giacomo, Alessia Covre, Maria Fortunata Lofiego, Lucio Crinò, Michele Maio	2024	3
4	LBA61 Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable stage III NSCLC: Final analysis from PACIFIC-6 Annals of Oncology ·M.C. Garassino, Julien Mazières, Martin Reck, C. Chouaïd, Helge Bischoff, Niels Reinmuth, Laura Cove-Smith, T. Mansy, Diego Cortinovis, M.R. Migliorino, Angelo Delmonte, J. García Sánchez, Luis Enrique Chara Velarde, Reyes Bernabé, Luis Paz‐Ares, P. Chander, I. Diaz Perez, K. Foroutanpour, Corinne Faivre‐Finn	2023	3
5	The Clinical Significance of Circulating Tumor DNA for Minimal Residual Disease Identification in Early-Stage Non-Small Cell Lung Cancer Life ·Alberto Verlicchi, Matteo Canale, Elisa Chiadini, Paola Cravero, Milena Urbini, Kalliopi Andrikou, Luigi Pasini, Michele Flospergher, Marco Angelo Burgio, Lucio Crinò, Paola Ulivi, Angelo Delmonte	2023	1
6	Genomic profiling in advanced NSCLC in Italy: First results of NERoNE (NSCLC Emilia Romagna Next Generation Sequencing Evaluation) project. Journal of Clinical Oncology ·Federica Bertolini, Giulia Alberti, Elisabetta Petracci, Stefania Bettelli, Paola Ulivi, Paola Cravero, Giorgia Guaitoli, Francesca Zanelli, Marco Angelo Burgio, Kalliopi Andrikou, Maria Pagano, Alberto Verlicchi, Daniele Calistri, Michele Flospergher, Luciana Mastrodomenico, Michela Maur, Katia Di Emidio, Massimo Dominici, Carmine Pinto, Angelo Delmonte	2023	0
7	Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer Cancers ·Valentina Danesi, Ilaria Massa, Flavia Foca, Angelo Delmonte, Lucio Crinò, Giuseppe Bronte, Maria Ragonesi, Roberta Maltoni, Silvia Manunta, Paola Cravero, Kalliopi Andrikou, Ilaria Priano, William Balzi, Nicola Gentili, Thomas Burke, Mattia Altini	2022	4
8	Combi-TED: A new Trial Testing Tedopi ^® with Docetaxel or Nivolumab in Metastatic Non-Small-Cell Lung Cancer Progressing After First Line Future Oncology ·Lorenza Landi, Angelo Delmonte, Andrea Bonetti, Giulia Pasello, Giulio Metro, Francesca Mazzoni, Gloria Borra, Diana Giannarelli, Kalliopi Andrikou, Daniela Mangiola, Stefania Gori, Mario D’Andrea, Gabriele Minuti, Blerina Resuli, Anastasia Laudisi, Antonello Vidiri, Laura Conti, Federico Cappuzzo	2022	2
9	How to discriminate non-small cell lung cancer (NSCLC) cases from an Italian administrative database? A retrospective, secondary data use study for evaluating a novel algorithm performance BMJ Open ·William Balzi, Andrea Roncadori, Valentina Danesi, Ilaria Massa, Silvia Manunta, Nicola Gentili, Angelo Delmonte, Lucio Crinò, Mattia Altini	2021	0
10	P2.01-15 Phase II Single Arm Study of CABozantinib in Non-Small Cell Lung Cancer Patients with MET Deregulation (CABinMET) Journal of Thoracic Oncology ·M. D’Arcangelo, Davide Tassinari, Filippo de Marinis, Angelo Delmonte, Domenico Galetta, Fabiana Letizia Cecere, Sara Pilotto, Francesca Zanelli, Laura Bonanno, Lorenza Landi, Federica D’Incà, Federico Cappuzzo	2019	9
11	EGFR mutation analysis for prospective patient (pt) selection in AURA3 Phase III trial of osimertinib vs platinum-pemetrexed (plt-pem) in pts with EGFR T790M positive advanced non-small cell lung cancer (NSCLC) Annals of Oncology ·Hiroaki Akamatsu, Angelo Delmonte, Thomas John, Wu‐Chou Su, Jin Sun Lee, G-C. Chang, X. Huang, Suzanne Jenkins, Simon Dearden, Yi‐Long Wu	2017	5
12	Intracranial efficacy of brigatinib (BRG) in patients (Pts) With crizotinib (CRZ)-refractory anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) and baseline CNS metastases Annals of Oncology ·S.-H.I. Ou, Marcello Tiseo, D. Ross Camidge, Myung‐Ju Ahn, Rudolf M. Huber, Maximilian J. Hochmair, S.-W. Kim, Howard West, Karen L. Reckamp, Julian R. Molina, G. Liu, Angelo Delmonte, Santiago Viteri, Alessandra Bearz, Yvonne Summers, William M. Reichmann, David Kerstein, Scott Gettinger, D.-W. Kim	2017	2
13	Impact of TP53 Mutations on Outcome in EGFR -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors Clinical Cancer Research ·Matteo Canale, Elisabetta Petracci, Angelo Delmonte, Elisa Chiadini, Claudio Dazzi, Maximilian Papi, Laura Capelli, Cláudia Casanova, Nicoletta De Luigi, Marita Mariotti, Alessandro Gamboni, Rita Chiari, Chiara Bennati, Daniele Calistri, Vienna Ludovini, Lucio Crinò, Dino Amadori, Paola Ulivi	2016	196
14	Efficacy and safety data from patients with advanced squamous NSCLC and brain metastases participating in the nivolumab Expanded Access Programme (EAP) in Italy Annals of Oncology ·Paolo Bidoli, Rita Chiari, Annamaria Catino, Francesco Grossi, Cristina Noberasco, Francesco Gelsomino, Marina Gilli, Claudia Proto, Héctor Soto Parrà, M.R. Migliorino, Lucia Bonomi, Davide Tassinari, Antonio Frassoldati, Valeria Albanese, Giovanni Maria Fadda, Francesco Cognetti, Federica De Galitiis, Giovanna Finocchiaro, Angelo Delmonte	2016	18
15	Crizotinib in ROS1 rearranged or MET deregulated Non-Small-Cell Lung Cancer (NSCLC): Preliminary results of the METROS trial Annals of Oncology ·L. Landi, Rita Chiari, Angelo Delmonte, A. Morabito, Stefano Tamberi, Fausto Barbieri, R. Buosi, Cesare Gridelli, Marcello Tiseo, Vittorio Gebbia, G. Fontanini, Lucio Crinò, Federico Cappuzzo	2016	2
16	Molecular Features and Clinical Outcome of Lung Malignancies in Very Young People Future Oncology ·Chiara Catania, Edoardo Botteri, Massimo Barberis, Fabio Conforti, Francesca Toffalorio, Filippo de Marinis, S. Boselli, Cristina Noberasco, Angelo Delmonte, Gianluca Spitaleri, Lorenzo Spaggiari, Nicole Rotmensz, Antonio Passaro, Barbara Bazolli, M. Alfieri, Michela Manzotti, Caterina Fumagalli, Alessandra Milani, Tommaso De Pas	2015	11
17	Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy Clinical Lung Cancer ·Paola Ulivi, Elisa Chiadini, Claudio Dazzi, Alessandra Dubini, Matteo Costantini, Laura Medri, Maurizio Puccetti, Laura Capelli, Daniele Calistri, Alberto Verlicchi, Alessandro Gamboni, Maximilian Papi, Marita Mariotti, Nicoletta De Luigi, Emanuela Scarpi, Sara Bravaccini, Gian Michele Turolla, Dino Amadori, Lucio Crinò, Angelo Delmonte	2015	75
18	Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors Annals of Oncology ·J.C. Soria, Filippo de Braud, Rastilav Bahleda, Bárbara Adamo, Fabrice André, R. Dientsmann, Angelo Delmonte, R. Cereda, J. Isaacson, Jason B. Litten, Andrew R. Allen, Frédéric Dubois, Chadi Saba, Renata Robert, Maurizio D’Incalci, Massimo Zucchetti, M.G. Camboni, Josep Tabernero	2014	147
19	Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors Clinical Cancer Research ·Cristiana Sessa, Patricia LoRusso, Anthony W. Tolcher, Françoise Farace, Nathalie Lassau, Angelo Delmonte, Antonio Braghetti, Rastislav Bahleda, Patrick Cohen, Marie Hospitel, Christine Veyrat‐Follet, Jean‐Charles Soria	2013	42
20	Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations Journal of Thoracic Oncology ·Tommaso De Pas, Francesca Toffalorio, Michela Manzotti, Caterina Fumagalli, Gianluca Spitaleri, Chiara Catania, Angelo Delmonte, Monica Giovannini, Lorenzo Spaggiari, Filippo de Braud, Massimo Barberis	2011	106

About Angelo Delmonte

Angelo Delmonte is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Gastroenterology and Hepatology, having authored 145 papers that have together received 2.7k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (86 papers), Cancer Immunotherapy and Biomarkers (34 papers), Lung Cancer Research Studies (31 papers), Cancer Genomics and Diagnostics (20 papers), Colorectal Cancer Treatments and Studies (19 papers), Lung Cancer Diagnosis and Treatment (16 papers), Hepatocellular Carcinoma Treatment and Prognosis (7 papers) and Economic and Financial Impacts of Cancer (7 papers). The work is most often cited by research in Oncology (1.4k citations), Pulmonary and Respiratory Medicine (1.6k citations), Cancer Research (689 citations), Pathology and Forensic Medicine (356 citations) and Hepatology (122 citations). Angelo Delmonte has collaborated with scholars based in Italy, United States and United Kingdom. Frequent co-authors include Lucio Crinò, Cristiana Sessa, Paola Ulivi, Giuseppe Bronte, Matteo Canale, Gianluca Spitaleri, Filippo de Braud, Daniele Calistri, Francesca Toffalorio and Rita Chiari. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Journal of Thoracic Oncology, Lung Cancer and Cancers.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact